Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
FDA Approves ZembraceSymTouch
Injectable sumatriptan succinate for migraine
Dr. Reddy's Laboratories announced that FDA has approved ZembraceSymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens. ZembraceSymTouch is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously.
Citation: Dr. Reddy’s Laboratories Ltd. receives FDA approval for ZEMBRACESymTouch (sumatriptan succinate) injection for the acute treatment of migraines in adults. [news release]. Princeton, NJ: Dr. Reddy’s Laboratories; January 29, 2016. http://www.drreddys.com/media/215069/press-release-zembrace-symtouch_29-jan-2016.pdf. Accessed February 4, 2016.
This Week's Must Reads
Must Reads in FDA Actions
FDA Approves Inbrija for PD OFF Episodes, Acorda Therapeutics news release; 2018 Dec 21
FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28
FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14
FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6
FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23